On March 5, Novo Nordisk released the top-line results from this pivotal kidney outcomes trial: Use of semaglutide in patients with diabetic kidney disease reduced the primary outcomea composite of kidney failure, 50% decline in estimated glomerular filtration rate (eGFR), and cardiovascular (CV) or kidney deathby an impressive 24% (Figure 1)
Tirzepatide: the dual-receptor comparison Tirzepatide adds GIP receptor activation to GLP-1, creating appetite suppression that is faster and stronger than semaglutide alone
When you stop a GLP-1 like semaglutide, effects gradually diminish over weeks, and your body does not suddenly rebound with blood sugar spikes or insulin deficiency
Why the Holidays Feel Different This Year: The GLP-1 Shift If youve started taking a GLP-1, holiday eating on them may feel and look different than in the past
Additionally, we summarized current clinical strategies for hormone therapy and antioxidant treatment, identified potential combination therapy approaches, and explored key challenges in their clinical translation
Pekala J, Patkowska-Sokola B, Bodkowski R, Jamroz D, Nowakowski P, Lochynski S, Librowski T (2011) L-carnitine-metabolic functions and meaning in humans life
![FortiWiFi-70G 5 Year FortiCare Elite Support [FC-10-FW70G-284-02-60] FortiCNAPP](https://cdn.shopify.com/s/files/1/0948/4127/4734/files/FC-10-FW70G-284-02-60.webp?v=1760601074)
